Entropy Neurodynamics Limited has released a press release.
$6.1m in new funding to accelerate clinical development
Filed with ASX ·
6ix hasn’t read this filing yet.
Entropy Neurodynamics Limited on 6ix
Earlier from Entropy Neurodynamics
- Trading Halt
- First patient enrolled in Binge Eating Disorder Trial
- Appendix 4E and 2025 Annual Report
- Landmark EEG Biomarker Agreement for Precision Psychiatry
- $2.6m in non-dilutive capital funding secured
Later from Entropy Neurodynamics
- BED trial accelerates - enrolment grows, dosing in two weeks
- First patient successfully dosed in TRP 8803 BED trial
- First BED patient completes second TRP-8803 infusion
- $847,186 R&D Tax Incentive received
- TRP-8802 Phase 2a Trial Shows Sustained BED Reduction
Follow Entropy Neurodynamics into a list and get an email when it puts out news.
Follow Entropy Neurodynamics